Innovus Pharma Provides Update on Its Signed Commercial Partnerships for Its Products

San Diego, CA, August 10, 2015 (Newswire.com) - ​Innovus Pharmaceuticals, Inc., (“Innovus Pharma”) www.innovuspharma.com (OTCQB: INNV) is pleased to provide an update on its signed commercial partnerships for its products. To date the Company has signed 9 commercial partnerships for its six products in 60 countries which entitle Innovus to over $475 million in potential sales milestones or/and either pre-agreed transfer price or double digit royalties.

The Company has a commercial pipeline of six products including:

1.      Zestra® for female for female sexual dysfunction

2.      EjectDelay® to treat premature ejaculation

3.      Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only)

4.      Zestra Glide® as a high viscosity low osmolality water based lubricant

5.      Vesele® for promoting sexual and cognitive health

6.      Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality

Please see image for a tabulated summary of the current signed partnerships detailing the partners, their territories and the terms.

Bassam Damaj, President and Chief Executive Officer of Innovus Pharma commented, "The Company has been very successful in partnering its products on a worldwide basis and although we have exceeded our goal of signing partners in 50 countries before year end, we are still going strong on finding strong commercial partners in every possible territories. Our goal has always been to commercialize our products in every possible country to allow us to grow fast to profitability and not be dependent on a single partner for our product”.

“In addition, the Company is currently negotiating 10 additional agreements and expects to start announcing the new partnerships throughout H2 2015,” continued Dr. Damaj.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health, vitality and respiratory diseases. The Company generates revenues from its lead products Zestra® for female arousal and EjectDelay® for premature ejaculation and has a total of five marketed products in this space, including Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), Zestra Glide®, Vesele® for promoting sexual and cognitive health and two products in the pipeline including, Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality and FlutiCare™ OTC for Allergic Rhinitis if approved by the FDA.

For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com

Innovus Pharma’s Forward-Looking Safe Harbor: Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, signed new commercial partners, receiving patent protection for any of its products, to receive approval or meet the requirements of any relevant regulatory authority and to increase the level of manufacturing with the current financing received by the Company. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

###

Innovus Pharma Contact:

Reuven Rubinson

Vice President of Finance

[email protected]

T: 858-964-5123